Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Oncology, and Metastasis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KARS/KARS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KARS1 Recombinant Protein (Full-Length & Active Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Available in E. coli or HEK293 expression systems. |
View KARS Products |
| Gene Delivery | KARS1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View KARS Products |
| Benchmark Ab | Anti-KARS1 Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IP assays. |
View KARS Products |
| Validator | KARS1 siRNA Set Target-specific knockdown verification in functional assays. |
View KARS Products |
| Related Target A | SDCBP (Syntenin-1) Interacts with cell-surface KARS to trigger cancer cell migration and metastasis. |
View SDCBP Products |
| Related Target B | MITF Transcription factor regulated by KARS-derived Ap4A in immunological signaling pathways. |
View MITF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing Cytosolic vs. Secreted KARS Functions | E. coli (for cytosolic catalytic assays) and HEK293 expressed (for native glycosylation/secreted interaction assays) proteins available. |
| Syntenin-1 (SDCBP) Interaction Blocking Screening | Highly purified, sequence-verified KARS and SDCBP proteins with theoretical MW verification for precise SPR/BLI binding assays. |
| Lack of Controls | Sequence-validated recombinant positive control antibodies and functional siRNA sets included. |
| False Positives in Enzymatic Assays | High purity (>95% by SDS-PAGE) ensures absence of host cell tRNA synthetase contamination. |
Live KARS/KARS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of KARS (Lysyl-tRNA Synthetase 1) is transitioning from its classical role in protein translation to its newly characterized non-canonical extracellular functions. KARS1 is highly upregulated in various microenvironments, where it translocates to the cell membrane or is secreted to promote cancer metastasis, trigger inflammatory cytokine cascades, and modulate immune responses.
The race for KARS/KARS1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum aminoacyl-tRNA synthetase inhibitors to highly selective small molecules and monoclonal antibodies blocking its extracellular interaction with Syntenin-1 (SDCBP). As first-generation therapies targeting tRNA synthetases reach the clinic for infectious and autoimmune diseases, the next wave of R&D is targeting the specific protein-protein interactions (PPI) of KARS1 in oncology and fibrotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Consortia | Fibrotic Diseases, Autoimmune Diseases, Parasitic Infections | Enzymatic activity assays requiring high-purity, active KARS1 recombinant protein. |
| Monoclonal Antibodies (Blocking) | Oncology-focused Biopharma | Metastatic Solid Tumors (Breast, Colon Cancer) | Surface binding and internalization assays (Requires native HEK293-expressed KARS1). |
| PPI Inhibitors (KARS-SDCBP) | Targeted Therapeutics Developers | Metastatic Cancers | High-throughput screening assays requiring both KARS1 and SDCBP recombinant proteins. |